GLP-1 weight loss drugs are changing the global pharmaceutical market. Products like Ozempic, Wegovy, and Mounjaro are now household names, and competition between drug makers is becoming more intense. As new companies enter this fast-growing market, the question is: who will come out on top?In this episode of Down to Business English, Skip Montreux and Dez Morgan get Down to Business with GLP-1 inhibitors — the drugs behind today’s weight-loss boom. They explain who the main players are, including Novo Nordisk and Eli Lilly, and compare their leading products. The discussion also looks at a major recent development: Pfizer’s acquisition of biopharma startup Metsera, and why this deal could significantly change the market.D2B 396 explores how strong demand, new research, and major acquisitions are reshaping the weight-loss drug market. As treatments become more effective and easier to use, competition is likely to increase even further.Do you like what you hear?Become a D2B Member today for to access to member-only episodes, our --NEW!!! -- INTERACTIVE AUDIO SCRIPTS, PDF Audio Script Library, Bonus Vocabulary episodes, and D2B Member-only episodes.Visit d2benglish.com/membership for more information.